[go: up one dir, main page]

WO2023111333A1 - Administration topique d'une composition comprenant 10 % p/v d'imidaclopride et 1 % p/v de moxidectine pour le traitement de la troglostrongylose chez les chats - Google Patents

Administration topique d'une composition comprenant 10 % p/v d'imidaclopride et 1 % p/v de moxidectine pour le traitement de la troglostrongylose chez les chats Download PDF

Info

Publication number
WO2023111333A1
WO2023111333A1 PCT/EP2022/086499 EP2022086499W WO2023111333A1 WO 2023111333 A1 WO2023111333 A1 WO 2023111333A1 EP 2022086499 W EP2022086499 W EP 2022086499W WO 2023111333 A1 WO2023111333 A1 WO 2023111333A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
troglostrongylus
infection
moxidectin
imidacloprid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2022/086499
Other languages
English (en)
Inventor
Hannah RINGEISEN
Gabriele Petry
Roland SCHAPER
Claudia BÖHM
Matthias POLLMEIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Animal Health GmbH
Elanco US Inc
Original Assignee
Bayer Animal Health GmbH
Elanco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health GmbH, Elanco US Inc filed Critical Bayer Animal Health GmbH
Priority to EP22840077.6A priority Critical patent/EP4447684A1/fr
Publication of WO2023111333A1 publication Critical patent/WO2023111333A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N51/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds having the sequences of atoms O—N—S, X—O—S, N—N—S, O—N—N or O-halogen, regardless of the number of bonds each atom has and with no atom of these sequences forming part of a heterocyclic ring

Definitions

  • the present invention relates to methods comprising topical administration of a composition comprising 1% w/v moxidectin and 10% w/v imidacloprid for the treatment of troglostrongylosis in cats.
  • the present invention provides methods comprising topical administration of a composition comprising 1% w/v moxidectin and 10% w/v imidacloprid for the treatment of troglostrongylosis in cats.
  • a method for the treatment of troglostrongylosis can comprise administration of an effective amount of a composition comprising moxidectin and imidacloprid to a feline in need thereof.
  • a method for treating a a Troglostrongylus infection can comprise administration of an effective amount of a composition comprising moxidectin and imidacloprid to a feline in need thereof.
  • the Troglostrongylus infection may be caused by a Troglostrongylus brevior infection.
  • a method for treating a Troglostrongylus infection can comprise administration of an effective amount of a composition comprising moxidectin and imidacloprid to a felid in need thereof.
  • a method for the treatment of felids suffering from or at risk from mixed parasitic infections can comprise administration of an effective amount of a composition comprising moxidectin and imidacloprid to a felid in need thereof.
  • the mixed parasitic infection can comprise flea infestation (Ctenocephalides felis , ear mite infestation (Otodectes cynolis), notoedric mange (Notoedres call , lungworm Eucoleus aerophilus (syn. Capillaria aerophild) (adults), lungworm disease (L3/L4 larvae of Aelurostrongylus abslriisiis).
  • a method for treating a Troglostrongylus infection comprising administration of an effective amount of a composition comprising moxidectin and imidacloprid to a ferret in need thereof.
  • the ferret is pregnant or lactating.
  • a method for the treatment of a ferret suffering from or at risk from mixed parasitic infections can comprise administration of an effective amount of a composition comprising moxidectin and imidacloprid to a ferret in need thereof.
  • the mixed parasitic infection can comprise flea infestation (Ctenocephalides felis), the prevention of heartworm disease (L3 and L4 larvae of Dirofdaria immilis). or a combination thereof.
  • the composition can comprise about 1 % w/v moxidectin and about
  • the feline can be a domestic cat (Felis catus).
  • the administration can be topical administration.
  • the composition can be administered once.
  • a method for the treatment of troglostrongylosis comprises administration of an effective amount of a composition comprising moxidectin and imidacloprid to a felid in need thereof.
  • a method for treating a Troglostrongylus infection can comprise administration of an effective amount of a composition comprising moxidectin and imidacloprid to a felid in need thereof.
  • the composition can comprise about 1% w/v moxidectin.
  • the composition can comprise between about 0.1% and 2% w/v moxidectin.
  • the composition can comprise about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, and 2% w/v moxidectin.
  • the composition can comprise about 1% w/v moxidectin.
  • the composition can comprise about 10% w/v imidacloprid.
  • the composition can comprise between about 5% and 15% w/v imidacloprid.
  • the composition can comprise about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, and 15% w/v imidacloprid.
  • the composition can comprise about 10% w/v imidacloprid.
  • the composition can comprise about 1% w/v moxidectin and about 10% w/v imidacloprid.
  • the troglostrongylosis is caused by a Troglostrongylus infection.
  • the troglostrongylosis may be caused by a Troglostrongylus brevior infection.
  • the troglostrongylosis can be caused by a Troglostrongylus infection.
  • the troglostrongylosis can be caused by a Troglostrongylus subcrenatus, Troglostrongylus brevior, and/or a Troglostrongylus wilsoni infection.
  • the troglostrongylosis can be caused by a Troglostrongylus brevior infection.
  • the effective amount can be between about 0.01 mL/Kg body weight (BW) and 0.5 mL/kg body weight.
  • the effective amount may be about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, or 0.5 mL/Kg body weight (BW) and 0.5 mL/kg body weight.
  • the effective amount may be about 0.1 mL/Kg body weight (BW).
  • the effective amount of the composition can be between about 0.01 mL/Kg body weight (BW) and 0.5 mL/kg body weight.
  • the effective amount of the composition can be about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, or 0.5 mL/Kg body weight (BW) and 0.5 mL/kg body weight.
  • the effective amount of the composition can be about 0.1 mL/Kg body weight (BW).
  • the feline can be a domestic cat (Felis catus).
  • the felid can be a domestic cat (Felis catus), wildcat Felis silvestris silvestris, Felis silvestris lybica), leopards (Panthera pardus), tiger (Panthera tigris) or a bobcat (Lynx rufus).
  • the felid can be a domestic cat Felis catus).
  • the administration can be subcutaneous, intramuscular, intravenous, intraperitoneal, intrapleural, intravesicular, intrathecal, topical, nasal, inhalation, oral administration, or a combination of routes.
  • the administration is topical administration.
  • the composition is administered once.
  • the composition can be administered once a week.
  • the composition can be administered every two weeks.
  • the composition can be administered once a month.
  • the composition can be administered for between about 1 and 6 months, optionally between about 1 and 3 months.
  • the composition can be administered once a month for about 12 months.
  • the composition can be administered after the completion of a course of treatment for heartworm.
  • the composition can be administered prior to infection.
  • the composition can be administered prior to manifestation of clinical signs of infection.
  • the composition can further comprise an adjuvant, carrier, buffers, antioxidants, wetting agents, lubricating agents, gelling agents, thickening agents, binding agents, disintegrating agents, humectants, preservatives, diluent, stabilizer, filler, excipient, or a combination thereof.
  • the excipient can be benzyl alcohol, Propylene carbonate, or a combination thereof.
  • the antioxidant can be butylhydroxytoluene.
  • the stabilizer can be triethanolamine, optionally comprising about 1% w/w or 2.5% w/w triethanolamine.
  • the composition can be a pharmaceutical composition.
  • the composition can be in the form of a liquid, foam, or gel.
  • the composition can be in the form of a liquid.
  • the composition can be administered prior to infection.
  • a composition for the treatment of a Troglostrongylus infection can comprise an effective amount of a composition comprising moxidectin and imidacloprid.
  • the composition can be formulated for subcutaneous, intramuscular, intravenous, intraperitoneal, intrapleural, intravesicular, intrathecal, topical, nasal, inhalation, oral administration, or a combination of routes.
  • the composition can be formulated for topical administration.
  • the composition can be formulated to be administered once.
  • the composition can be formulated as a unit dosage.
  • the unit dose can be 0.4 mL or 0.8 mL.
  • the unit dosage can be about 0.4 mL comprising about 40 mg imidacloprid and 4 mg moxidectin.
  • the unit dosage can be about 0.8 mL comprising about 80 mg imidacloprid and 8 mg moxidectin.
  • Feline troglostrongylosis is characterized by catarrhal bronchitis and interstitial pneumonia, which are particularly severe and potentially life threatening in kittens and young animals. Infected cats display ocular-nasal discharge, sneezing, dyspnea, tachypnea, cough, and non-specific clinical signs, e.g., hypo- or anorexia, hyperthermia, dehydration. Despite the growing importance of troglostrongylosis in feline medicine, control options are still limited.
  • compositions described herein can also be used for treating ferrets with trogl ostrongyl osi s .
  • compositions described herein can comprise between about 0.1% and 2% w/v moxidectin.
  • the composition can comprise about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, and 2% w/v moxidectin.
  • the composition can comprise about 1% w/v moxidectin.
  • the composition described herein can comprise between about 5% and 15% w/v imidacloprid.
  • the composition can comprise about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, and 15% w/v imidacloprid.
  • the composition can comprise about 10% w/v imidacloprid.
  • the troglostrongylosis can be caused by a Troglostrongylus infection.
  • the troglostrongylosis can be caused by a Troglostrongylus subcrenatus .
  • the troglostrongylosis can be caused by a Troglostrongylus brevior infection.
  • the felid treated by the methods described herein can be a domestic cat Felis catus), wildcat (Felis silvestris silvestris, Felis silvestris lybica), leopards (Panthera pardus), tiger (Panthera tigris) or a bobcat (Lynx rufus).
  • the felid can be a domestic cat (Felis catus).
  • compositions and methods described herein can be used in the treatment of felids suffering from or at risk from mixed parasitic infections.
  • the compositions and methods described herein can be used in the treatment and prevention of flea infestation (Ctenocephalides felis), ear mite infestation (Otodectes cynolis), notoedric mange (Notoedres call), lungworm Eucoleus aerophilus (syn.
  • Capillaria aerophila (adults), lungworm disease (L3/L4 larvae of Aelurostrongylus abstrusus), lungworm Aelurostrongylus abstrusus (adults), lungworm Troglostrongylus brevior (adults), eye worm Thelazia callipaeda (adults), heartworm disease (L3 and L4 larvae of Dirofilaria immitis), infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara cati and Ancylostoma tubaeforme), and combinations thereof.
  • the compositions and methods described herein can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
  • compositions and methods described herein can be used in the treatment of ferrets suffering from or at risk from mixed parasitic infections.
  • the compositions and methods described herein can be used in the treatment and prevention of flea infestation (Ctenocephalides felis , the prevention of heartworm disease (L3 and L4 larvae of Dirofdaria immitis), or a combination thereof.
  • compositions described herein can be used for the treatment of a Troglostrongylus infection.
  • compositions described herein can be used for the treatment of a felid suffering from or at risk from mixed parasitic infections.
  • the mixed parasitic infection can comprise flea infestation (Ctenocephalides felis), ear mite infestation (Otodectes cynotis), notoedric mange (Notoedres cati), lungworm Eucoleus aerophilus (syn.
  • Capillaria aerophila (adults), lungworm disease (L3/L4 larvae of Aelurostrongylus abstrusus), lungworm Aelurostrongylus abstrusus (adults), lungworm Troglostrongylus brevior (adults), eye worm Thelazia callipaeda (adults), heartworm disease (L3 and L4 larvae of Dirofilaria immitis), infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara cati and Ancylostoma lubaeforme . and combinations thereof.
  • compositions described herein can be used for the treatment of a ferret suffering from or at risk from mixed parasitic infections.
  • the mixed parasitic infection can comprise flea infestation (Ctenocephalides felis), the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immilis). or a combination thereof.
  • compositions described herein can be used for the treatment of flea allergy dermatitis (FAD).
  • a method for the treatment of flea allergy dermatitis (FAD) in a felid can comprise administration of an effective amount of a composition comprising moxidectin and imidacloprid to a felid in need thereof.
  • compositions described herein can be used for the treatment of flea allergy dermatitis (FAD).
  • a method for the treatment of flea allergy dermatitis (FAD) in a ferret can comprise administration of an effective amount of a composition comprising moxidectin and imidacloprid to a felid in need thereof.
  • compositions comprising imidacloprid and moxidectin described herein can be formulated into a pharmaceutical composition.
  • the composition including pharmaceutical compositions, can comprise an adjuvant, carrier, buffers, antioxidants, wetting agents, lubricating agents, gelling agents, thickening agents, binding agents, disintegrating agents, humectants, preservatives, diluent, stabilizer, filler, excipient, or a combination thereof.
  • the excipient can be benzyl alcohol.
  • the antioxidant can be butylhydroxytoluene.
  • the excipient can be benzyl alcohol, propylene carbonate, or a combination thereof.
  • the stabilizer can be triethanolamine.
  • the composition, optionally pharmaceutical compositions can be in the form of a liquid, foam, or gel.
  • the composition, optionally pharmaceutical compositions can be in the form of a liquid.
  • compositions described herein may be formulated as a pharmaceutical composition comprising imidacloprid and moxidectin and pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers include, but are not limited to, excipient, lubricant, emulsifier, stabilizer, solvent, diluent, buffer, vehicle, or a combination thereof.
  • the excipient can be benzyl alcohol, propylene carbonate, or a combination thereof.
  • the antioxidant can be butylhydroxytoluene.
  • the stabilizer can be triethanolamine.
  • Pharmaceutically acceptable carriers include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil or injectable organic esters.
  • Pharmaceutically acceptable carriers may be a liquid, including but not limited to water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil.
  • the pharmaceutical carriers may be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, or urea.
  • auxiliary, stabilizing, thickening, lubricating and coloring agents may be used.
  • sugars and/or amino acids may be admixed into the pharmaceutical composition.
  • the pharmaceutical composition can comprise water, glycerin, phospholipids, or a mixture thereof.
  • suitable pharmaceutical carriers are described in Remington’s Pharmaceutical Sciences (Alfonso Gennaro ed., Krieger Publishing Company (1997); Remington’s: The Science and Practice of Pharmacy, 21 st Ed. (Lippincot, Williams & Wilkins (2005); Modern Pharmaceutics, vol. 121 (Gilbert Banker and Christopher Rhodes, CRC Press (2002).
  • the pharmaceutical carrier can be either solid or liquid.
  • Solid form preparations include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories.
  • a solid carrier can be one or more substances that can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
  • compositions can include the formulation of imidacloprid and moxidectin with encapsulating material as a carrier providing a capsule in which the inhibitor (with or without other carriers) is surrounded by the carrier, such that the carrier is thus in association with the compounds.
  • encapsulating material such as a carrier providing a capsule in which the inhibitor (with or without other carriers) is surrounded by the carrier, such that the carrier is thus in association with the compounds.
  • cachets can also be included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
  • Liquid pharmaceutical compositions include, for example, solutions suitable for oral or parenteral administration, suspensions, and emulsions suitable for oral administration.
  • Sterile water solutions of the active component e.g., imidacloprid and moxidectin, or sterile solutions of the active component in solvents comprising water, buffered water, saline, PBS, ethanol, or propylene glycol are examples of liquid compositions suitable for parenteral administration.
  • the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, detergents, and the like.
  • compositions can be carried out with dose levels and pattern being selected by the treating veterinarian.
  • pharmaceutical formulations should provide a quantity of imidacloprid and moxidectin effective to treat cat troglostrongylosis, either therapeutically or prophylactically.
  • compositions comprising imidacloprid and moxidectin described herein can be administered by a route selected from the group consisting of subcutaneous, intramuscular, intravenous, intraperitoneal, vaginal, rectal, intrapleural, intravesicular, intrathecal, topical, nasal, inhalation, oral administration, or a combination of routes.
  • the digested material was filtered using 200 pm and 180 pm sieves, in Study 1 and 2 respectively, and centrifuged in 50 mL tubes at 300 g for 10 minutes (Study 1) or and at 600 g for 5 minutes (Study 2).
  • the sediment was resuspended in tap water and the centrifugation step was repeated; it was then pooled, shaken and the larval suspension was set on a magnetic stirrer with heating plate (about 41°C). While stirring, 10 aliquots of 0. 1 mL suspension each were smeared onto glass slides to calculate the mean number of larvae in 0.1 mL. Based on this average, an inoculum volume containing approximately 100 L3 was prepared for the inoculation in both studies.
  • a stomach tube was inserted without (Study 1) or with a rigid endoscope (Study 2).
  • the inoculum was applied via syringe directly into the stomach, the tube was flushed with tap water and pulled out after confirming that no inoculation suspension remained in the tube .
  • All cats were observed for vomiting or regurgitation directly after inoculation for up to 1 hour ( ⁇ 10 minutes) post infection.
  • N2 GM count of T. brevior for GI
  • Troglostrongylus brevior adult worms were found in 4/8 and 4/10 untreated (G I ) animals in Study 1 and 2, respectively. All worms were either viable or recently dead and intact. In two of these cats, 202 additionally living larvae and eggs of T brevior were found. No adult T. brevior worms or other development stages were detected in any of cats treated with Advocate® (Table 7).
  • Troglostrongylus brevior is an emerging nematode which may cause severe parasitic bronchopneumonia. The disease can be life-threatening especially for kittens and young animals and permanent damages, such as irreversible pulmonary hypertension and chronic complications, may occur. Subclinical infections are also of importance, as undiagnosed cats represent a source of infection for intermediate hosts. Effective treatments are thus critically important to cure infected cats with respiratory signs and to stop larval shedding and interrupt the life cycle of T. brevior.
  • Non-Patent Literature All publications (e.g., Non-Patent Literature), patents, patent application publications, and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All such publications (e.g., Non-Patent Literature), patents, patent application publications, and patent applications are herein incorporated by reference to the same extent as if each individual publication, patent, patent application publication, or patent application was specifically and individually indicated to be incorporated by reference.
  • Aspect 1 A method for the treatment of troglostrongylosis comprising administration of an effective amount of a composition comprising moxidectin and imidacloprid to a feline in need thereof.
  • Aspect 2 The method of aspect 1, wherein the composition comprises about 1 % w/v moxidectin.
  • Aspect 3 The method of aspect 1 or 2, wherein the composition comprises about 10% w/v imidacloprid.
  • Aspect 4 The method of any one of aspects 1-3, wherein the troglostrongylosis is caused by a Troglostrongylus infection.
  • Aspect 5 The method of any one of aspects 1-4, wherein the troglostrongylosis is caused by a Troglostrongylus brevior infection.
  • Aspect 6 The method of any one of aspects 1-5, wherein the effective amount is between about 0.01 mL/Kg body weight (BW) and 0.5 mL/kg body weight.
  • Aspect 7 The method of any one of aspects 1-6, wherein the effective amount is about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, or 0.5 mL/Kg body weight (BW) and 0.5 mL/kg body weight.
  • Aspect 8 The method of any one of aspects 1-7, wherein the effective amount is about 0.1 mL/Kg body weight (BW).
  • Aspect 9 The method of any one of aspects 1-8, wherein the feline is a domestic cat (Fells catus).
  • Aspect 10 The method of any one of aspects 1-9, wherein the administration is topical administration.
  • Aspect 11 The method of any one of aspects 1-10, wherein the composition is administered once.
  • a method for treating a a Troglostrongylus infection comprising administration of an effective amount of a composition comprising moxidectin and imidacloprid to a feline in need thereof.
  • Aspect 13 The method of aspect 12, wherein the composition comprises about 1 % w/v moxidectin.
  • Aspect 14 The method of aspect 12 or 13, wherein the composition comprises about 10% w/v imidacloprid.
  • Aspect 15 The method of any one of aspects 12-14, wherein the Troglostrongylus infection is caused by a Troglostrongylus brevior infection.
  • Aspect 16 The method of any one of aspects 12-15, wherein the effective amount is between about 0.01 mL/Kg body weight (BW) and 0.5 mL/kg body weight.
  • Aspect 17 The method of any one of aspects 12-16, wherein the effective amount is about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, or 0.5 mL/Kg body weight (BW) and 0.5 mL/kg body weight.
  • Aspect 18 The method of any one of aspects 12-17, wherein the effective amount is about
  • Aspect 19 The method of any one of aspects 12-18, wherein the feline is a domestic cat (Felis catus).
  • Aspect 20 The method of any one of aspects 12-19, wherein the administration is topical administration.
  • Aspect 21 The method of any one of aspects 12-20, wherein the composition is administered once.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés d'administration topique d'une composition comprenant 1 % p/v m d'oxidectine et 10 % p/v d'imidaclopride pour le traitement de la troglostrongylose chez les chats.
PCT/EP2022/086499 2021-12-17 2022-12-16 Administration topique d'une composition comprenant 10 % p/v d'imidaclopride et 1 % p/v de moxidectine pour le traitement de la troglostrongylose chez les chats Ceased WO2023111333A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22840077.6A EP4447684A1 (fr) 2021-12-17 2022-12-16 Administration topique d'une composition comprenant 10 % p/v d'imidaclopride et 1 % p/v de moxidectine pour le traitement de la troglostrongylose chez les chats

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163291136P 2021-12-17 2021-12-17
US63/291,136 2021-12-17

Publications (1)

Publication Number Publication Date
WO2023111333A1 true WO2023111333A1 (fr) 2023-06-22

Family

ID=84901662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/086499 Ceased WO2023111333A1 (fr) 2021-12-17 2022-12-16 Administration topique d'une composition comprenant 10 % p/v d'imidaclopride et 1 % p/v de moxidectine pour le traitement de la troglostrongylose chez les chats

Country Status (2)

Country Link
EP (1) EP4447684A1 (fr)
WO (1) WO2023111333A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662309B2 (en) * 2004-11-09 2017-05-30 Bayer Intellectual Property Gmbh Anti-demodicosis agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662309B2 (en) * 2004-11-09 2017-05-30 Bayer Intellectual Property Gmbh Anti-demodicosis agent

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Ophthalmic and topical dosage form new animal drugs; imidacloprid and moxidectin", vol. 72, 3 September 2007, FEDERAL REGISTER (2007), 72(46), 10597-10598, 9 MAR 2007 CODEN: FEREAC; ISSN: 0097-6326, Federal Register (2007), 72(46), 10597-10598, 9 Mar 2007 CODEN: FEREAC; ISSN: 0097-6326, pages: 10597 - 10598, XP009543422 *
"Remington's Pharmaceutical Sciences", 1997, KRIEGER PUBLISHING COMPANY
"Remington's: The Science and Practice of Pharmacy", 2005, LIPPINCOT, WILLIAMS & WILKINS
DI CESARE ET AL., PARASITOL RES, vol. 112, no. 9, 2013, pages 3101 - 3108
DIAKOU ET AL.: "Efficacy of a moxidectin/imidacloprid spot-on formulation (Advocate®) for the treatment of Troglostrongylus brevior in naturally infected cats in a field study in Greece", PARASITES & VECTORS, vol. 12, no. 1, 4 November 2019 (2019-11-04), pages 1 - 5, XP009543409 *
GILBERT BANKERCHRISTOPHER RHODES: "Modern Pharmaceutics", vol. 121, 2002, CRC PRESS
MICHAEL W DRYDEN ET AL: "Efficacy of imidacloprid + moxidectin and selamectin topical solutions against the KS1 Ctenocephalides felis flea strain infesting cats", PARASITES & VECTORS, BIOMED CENTRAL LTD, LONDON UK, vol. 4, no. 1, 13 September 2011 (2011-09-13), pages 174, XP021111264, ISSN: 1756-3305, DOI: 10.1186/1756-3305-4-174 *
MORELLI ET AL., PATHOGENS, vol. 10, no. 8, 2021, pages 960
MORELLI ET AL., VET PARASITOL, vol. 282, 2020, pages 109123
TAWEETHAVONSAWAT PIYANAN ET AL: "Efficacy of a spot on combination containing imidacloprid 10% and moxidectin 1% (Advocate /Advantage Multi, Bayer Animal Health) againstAncylostoma ceylanicumin cats", VETERINARY PARASITOLOGY, vol. 190, no. 1, 2012, pages 289 - 293, XP028944276, ISSN: 0304-4017, DOI: 10.1016/J.VETPAR.2012.05.008 *
VENCO L ET AL: "Field efficacy and safety of a combination of moxidectin and imidacloprid for the prevention of feline heartworm (Dirofilaria immitis) infection", VETERINARY PARASITOLOGY, ELSEVIER SCIENCE, AMSTERDAM, NL, vol. 154, no. 1-2, 14 June 2008 (2008-06-14), pages 67 - 70, XP022648218, ISSN: 0304-4017, [retrieved on 20080304], DOI: 10.1016/J.VETPAR.2008.02.020 *

Also Published As

Publication number Publication date
EP4447684A1 (fr) 2024-10-23

Similar Documents

Publication Publication Date Title
Burke et al. Sustainable approaches to parasite control in ruminant livestock
Bordes et al. First report of multiple resistance to eprinomectin and benzimidazole in Haemonchus contortus on a dairy goat farm in France
Sykes Parasitism and production in farm animals
Tzamaloukas et al. The effect of chicory (Cichorium intybus) and sulla (Hedysarum coronarium) on larval development and mucosal cell responses of growing lambs challenged with Teladorsagia circumcincta
Haile et al. Effects of breed and dietary protein supplementation on the responses to gastrointestinal nematode infections in Ethiopian sheep
Hamel et al. Eprinomectin pour-on (EPRINEX® Pour-on, Merial): efficacy against gastrointestinal and pulmonary nematodes and pharmacokinetics in sheep
JP2023532029A (ja) コクシジウム症の予防と治療に対する、動物飼料によるプラスの潜在的効果
Willette et al. Management of select bacterial and parasitic conditions of raptors
Rahmann et al. Alternative management strategies to prevent and control endo-parasite diseases in sheep and goat farming systems-a review of the recent scientific knowledge
Manzano-Román et al. Antigens from the midgut membranes of Ornithodoros erraticus induce lethal anti-tick immune responses in pigs and mice
Vatta et al. Persistence of the efficacy of copper oxide wire particles against Haemonchus contortus in grazing South African goats
Idika et al. Changes in the body condition scores of Nigerian West African Dwarf sheep experimentally infected with mixed infections of Haemonchus contortus and Trichostrongylus colubriformis
WO2023111333A1 (fr) Administration topique d'une composition comprenant 10 % p/v d'imidaclopride et 1 % p/v de moxidectine pour le traitement de la troglostrongylose chez les chats
Nordkvist et al. A comparative study on the efficacy of four anthelmintics on some important reindeer parasites
Max et al. Effect of quebracho tannin on faecal egg counts and worm burdens of temperate sheep with challenge nematode infections
Balmer et al. Strategic control of gastrointestinal nematodes in grazing sheep with a long-acting moxidectin formulation
Traversa et al. Efficacy of a spot-on combination containing 10% w/v imidacloprid and 1% w/v moxidectin for the treatment of troglostrongylosis in experimentally infected cats
Balicka-Ramisz et al. The annual population dynamics of gastrointestinal nematodes in breeding sheep of the Silesian Foothills, southern Poland
Štrbac et al. Anthelmintic resistance in gastrointestinal nematodes of sheep: Current situation and novel strategies
Young The Effect of the Nematode Trapping Fungus Duddingtonia flagrans Against Gastronintestinal Nematodes of Exotic Ruminant Hoofstock at Disney's (R) Animal Kingdom Lodge
RU2136303C1 (ru) Способ получения средства для лечения ларвального и стробилярного эхинококкозов "чеблин ск-1"
Bartley Prevalence, characterisation and management of anthelmintic resistance in gastro-intestinal nematodes of Scottish sheep
Khoris et al. Effect of Artemisia extract on Argulus coregoni and Lernaea cyprinacea infestation in carp fish
George Interactions and epidemiology of nematode worm control in livestock
Akkaya et al. Effect of praziquantel on Dicrocoelium dendriticum in naturally infected sheep

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22840077

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2022840077

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022840077

Country of ref document: EP

Effective date: 20240717